A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
06
02
2022
accepted:
03
01
2023
medline:
29
3
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Metabolic rewiring is often considered an adaptive pressure limiting metastasis formation; however, some nutrients available at distant organs may inherently promote metastatic growth. We find that the lung and liver are lipid-rich environments. Moreover, we observe that pre-metastatic niche formation increases palmitate availability only in the lung, whereas a high-fat diet increases it in both organs. In line with this, targeting palmitate processing inhibits breast cancer-derived lung metastasis formation. Mechanistically, breast cancer cells use palmitate to synthesize acetyl-CoA in a carnitine palmitoyltransferase 1a-dependent manner. Concomitantly, lysine acetyltransferase 2a expression is promoted by palmitate, linking the available acetyl-CoA to the acetylation of the nuclear factor-kappaB subunit p65. Deletion of lysine acetyltransferase 2a or carnitine palmitoyltransferase 1a reduces metastasis formation in lean and high-fat diet mice, and lung and liver metastases from patients with breast cancer show coexpression of both proteins. In conclusion, palmitate-rich environments foster metastases growth by increasing p65 acetylation, resulting in a pro-metastatic nuclear factor-kappaB signaling.
Identifiants
pubmed: 36732635
doi: 10.1038/s43018-023-00513-2
pii: 10.1038/s43018-023-00513-2
pmc: PMC7615234
mid: EMS172138
doi:
Substances chimiques
NF-kappa B
0
Carnitine O-Palmitoyltransferase
EC 2.3.1.21
Acetyl Coenzyme A
72-89-9
Palmitates
0
Lysine Acetyltransferases
EC 2.3.1.32
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
344-364Subventions
Organisme : Arthritis Research UK
ID : FC001112
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001112
Pays : United Kingdom
Organisme : European Research Council
ID : 771486
Pays : International
Organisme : European Research Council
ID : 773208
Pays : International
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001112
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001112
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Cancer Cell. 2015 Feb 9;27(2):177-92
pubmed: 25670079
Front Oncol. 2022 Sep 23;12:988872
pubmed: 36338708
Science. 2019 Feb 8;363(6427):644-649
pubmed: 30733421
Pharm Biol. 2014 Nov;52(11):1460-6
pubmed: 24963944
Sci Adv. 2021 Oct 08;7(41):eabh2443
pubmed: 34613780
Stem Cell Res. 2018 Dec;33:25-35
pubmed: 30308415
J Mass Spectrom. 1996 Mar;31(3):255-62
pubmed: 8799277
Cell Metab. 2019 Apr 2;29(4):886-900.e5
pubmed: 30661930
Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50
pubmed: 25053359
Cancer Res. 2021 Apr 15;81(8):1988-2001
pubmed: 33687947
J Lipid Res. 2014 Jul;55(7):1478-88
pubmed: 24859739
Bio Protoc. 2016 Nov 20;6(22):
pubmed: 28180137
J Clin Invest. 2004 Aug;114(4):569-81
pubmed: 15314694
Cell Rep. 2016 Mar 8;14(9):2154-2165
pubmed: 26923594
Breast Cancer Res. 2000;2(5):331-4
pubmed: 11250725
EMBO J. 2014 Sep 1;33(17):1912-27
pubmed: 25024434
Genes Dev. 2009 Apr 1;23(7):849-61
pubmed: 19339690
Nat Commun. 2018 Feb 5;9(1):493
pubmed: 29402958
Nat Commun. 2017 May 11;8:15267
pubmed: 28492237
Mol Cell. 2020 Jan 2;77(1):120-137.e9
pubmed: 31733993
Nat Protoc. 2011 Feb;6(2):147-57
pubmed: 21293456
Nature. 2019 Feb;566(7744):403-406
pubmed: 30728499
Biomed Pharmacother. 2018 Oct;106:1-7
pubmed: 29940537
Trends Biochem Sci. 2008 Jul;33(7):339-49
pubmed: 18585916
Methods Mol Biol. 2019;1862:53-66
pubmed: 30315459
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1204-9
pubmed: 15504342
Nature. 2019 Apr;568(7750):117-121
pubmed: 30814728
Methods Enzymol. 2016;574:3-29
pubmed: 27423855
Nat Rev Cancer. 2021 Mar;21(3):162-180
pubmed: 33462499
Cancers (Basel). 2021 Sep 24;13(19):
pubmed: 34638280
Cell Rep. 2016 Oct 11;17(3):837-848
pubmed: 27732858
Nature. 2021 Nov;599(7884):302-307
pubmed: 34671163
Cancer Cell. 2009 Jan 6;15(1):35-44
pubmed: 19111879
Cell Metab. 2021 Oct 5;33(10):2040-2058.e10
pubmed: 34559989
Cancer Discov. 2014 Apr;4(4):466-79
pubmed: 24513958
Mol Cancer Res. 2020 Jul;18(7):1088-1098
pubmed: 32198139
Curr Opin Biotechnol. 2015 Aug;34:189-201
pubmed: 25731751
Cell Metab. 2022 Nov 1;34(11):1675-1699
pubmed: 36261043
Biochem Biophys Res Commun. 2007 Jun 22;358(1):150-5
pubmed: 17467667
Clin Exp Metastasis. 2014 Jan;31(1):67-79
pubmed: 23963763
Nature. 2019 Aug;572(7771):603-608
pubmed: 31462798
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Cancer Res. 2012 Aug 15;72(16):3906-11
pubmed: 22751463
Clin Sci (Lond). 2021 Jan 15;135(1):231-257
pubmed: 33443284
Blood. 2022 Jan 20;139(3):384-398
pubmed: 34232979
Mol Cell. 2018 Aug 2;71(3):398-408
pubmed: 30075141
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Biochem Cell Biol. 2019 Feb;97(1):30-45
pubmed: 29671337
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
Nat Cancer. 2020 Jun;1(6):603-619
pubmed: 34124690
Nature. 2021 Nov;599(7885):485-490
pubmed: 34759321
Front Oncol. 2019 Apr 24;9:219
pubmed: 31069166
iScience. 2021 Oct 07;24(11):103244
pubmed: 34746707
Oncotarget. 2016 Apr 12;7(15):19982-96
pubmed: 26799588
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Semin Cancer Biol. 2020 Feb;60:274-284
pubmed: 31491560
Nat Cancer. 2021 Apr;2(4):414-428
pubmed: 34179825
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Mol Cell. 2021 Jan 21;81(2):386-397.e7
pubmed: 33340488
Oncogene. 2018 Nov;37(46):6025-6040
pubmed: 29995871
Cell Metab. 2017 Dec 5;26(6):842-855.e5
pubmed: 29056512
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
NAR Cancer. 2021 Sep 09;3(3):zcab035
pubmed: 34514415
Oncogene. 2009 Aug 27;28(34):3022-32
pubmed: 19543317
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Lipids Health Dis. 2020 Jun 3;19(1):122
pubmed: 32493486
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
EMBO Rep. 2020 Oct 5;21(10):e50635
pubmed: 32964587
J Med Chem. 2009 Jan 22;52(2):530-6
pubmed: 19099397
Adv Bioinformatics. 2008;2008:420747
pubmed: 19956698
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Blood. 2019 Oct 17;134(16):1323-1336
pubmed: 31492675
Metab Eng. 2017 Sep;43(Pt B):187-197
pubmed: 27847310
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Nat Rev Cancer. 2011 Nov 24;11(12):886-95
pubmed: 22113164
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Breast Cancer Res Treat. 2000 Jul;62(1):51-62
pubmed: 10989985
Cell Metab. 2018 Dec 4;28(6):881-894.e13
pubmed: 30146488
J Nutr. 2005 Aug;135(8):1841-6
pubmed: 16046706
Dev Cell. 2021 May 17;56(10):1363-1393
pubmed: 33945792
Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1370-5
pubmed: 19542021
J Clin Invest. 2013 Jul;123(7):3025-36
pubmed: 23921127
Nat Cell Biol. 2008 Nov;10(11):1349-55
pubmed: 18820689
Cell Rep. 2016 Nov 1;17(6):1463-1472
pubmed: 27806287
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14635-40
pubmed: 16192349
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Bone. 2019 Jan;118:53-61
pubmed: 29258874